2016-03-11 11:38
（吉隆坡10日訊）儘管分析員顧慮科鼎控股（BIOHLDG,0179,創業板消費品組）市值太小，但仍看好其長期業務展望。
聯昌研究指出，目前該公司的潛在利好包括中國和印尼銷售超越預期及MyAngkasa合作項目進度加快。
目前，印尼貢獻近半營業額，是最大市場。2015年第二季啟動的中國業務，則在短時間內崛起成為第二大市場。
該公司與擁有8千家合作社和800萬會員的MyAngkasa聯營零售醫藥業務，放眼透過特許經營模式在全國各地開設店面。
聯昌鑒於該公司市值太小，而將評估基礎從2017年16.5倍本益比溢價20%，轉為2017年25年倍本益比折價20%，目標價和評級保持65仙和“加碼”。（星洲日報／財經）
| Chart | Stock Name | Last | Change | Volume |
|---|
Time
Signal
Duration
Type
2024-11-22 12:10:00
EMA 5
10 Mins
SELL
2024-11-22 12:05:00
EMA 5
5 Mins
SELL
2024-11-22 12:05:00
ADX
5 Mins
SELL
2024-11-22 12:05:00
TURTLE SYSTEM 20
5 Mins
SELL
2024-11-22 12:00:00
ADX
10 Mins
SELL
2
3
BFM Podcast
4
5
BFM Podcast
6
Axcapital's investment blog
KAB - Executing its way to a record quarter. Could more Petronas contracts be coming?
7
Koon Yew Yin's Blog
CPO price is rising rapidly as shown by chart below - Koon Yew Yin
8
Mercury Securities Research
#
Stock
Score
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
